Across TCGA pan-cancer cohorts, PTPRCAP RNA is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PTPRCAP data layer compared with 5 for mutation status and 4 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher PTPRCAP RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated PTPRCAP expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.
SCLC are the cancer types where PTPRCAP RNA most reproducibly stratifies survival.